Gradient Denervation Technologies Expands Pulmonary Hypertension Trial and Appoints Stanton Rowe to Board
• Gradient Denervation Technologies appointed Stanton Rowe, a medical device entrepreneur, to its board of directors to leverage his expertise in medical technology development.
• The FDA approved the expansion of Gradient's PreVail-PH2 Early Feasibility Study for their ultrasound-based pulmonary artery denervation technology.
• The study is enrolling patients with WHO Group 2 Pulmonary Hypertension at multiple centers in the United States to assess the safety and efficacy.
• Gradient's minimally invasive device aims to provide a novel treatment option for pulmonary hypertension patients with associated heart failure, addressing an unmet need.
© Copyright 2025. All Rights Reserved by MedPath